PDL BioPharma, Inc. (NASDAQ:PDLI)

CAPS Rating: 3 out of 5

A biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses.

Recs

0
Player Avatar myfairshare (< 20) Submitted: 8/17/2012 6:04:53 PM : Outperform Start Price: $6.82 PDLI Score: -0.52

I think the royalties are the best position to be in, for the pharmaceutical plays.

Featured Broker Partners


Advertisement